Intracerebral Hemorrhage Clinical Trial
Official title:
Biomarkers and Imaging Markers Screening for Intracerebral Hemorrhage Patients
Intracerebral hemorrhage (ICH) is a subtype of stroke associated with high mortality and disability. Basic and clinical research has contributed to our understanding of the complex pathophysiology in ICH. However, questions regarding acute diagnosis, therapeutic decisions, and prognostication of ICH remain unanswered. Molecular biomarkers and imaging markers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction and magnetic resonance imaging (MRI) scan in ischemic stroke. Therefore, the investigators aim to discovery the potential biomarkers by screening samples of blood, cerebral spinal fluid, urine, saliva, and even tissues (if available) from ICH patients, and imaging markers via serial multimodality imaging scans such as computed tomography(CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), etc. These molecular and imaging markers would assist in contributing additional information to current tools for onset warning, diagnosis, therapy monitoring, risk stratification, intervention and prognosis for ICH patients.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 1, 2026 |
Est. primary completion date | June 1, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Individuals aged 18-80 years 2. Hematoma size is more than 5 ml 3. Evidence of a spontaneous ICH on CT scan 4. Patient within 72 hours of ictus 5. Glasgow Coma Scale (GCS) Score of 5-15. 6. The history of hypertension Exclusion Criteria: 1. Individuals with age < 18 years or > 80 years 2. Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases. 3. ICH secondary to tumor or trauma.. 4. If the haematological effects of any previous anticoagulants are not completely reversed. 5. Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction. |
Country | Name | City | State |
---|---|---|---|
China | Department of Neurosurgery , Southwest Hospital, Third Military Medical University, | Chongqing | Chongqing |
Lead Sponsor | Collaborator |
---|---|
Southwest Hospital, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Biomarkers | Diseased tissue from the patient is collected at the time of hematoma removal. These tissues are then immediately prepared and detected by proteome mass spectrometry. The results will be further analyzed by bioinformatics analysis to reveal the expression of proteins in the diseased tissues of patients with intracerebral hemorrhage as potential biomarkers. | Immediately after collecting tissues | |
Primary | CT imaging features | Patients will undergo CT imaging examinations to evaluate the patient's hematoma volume, hematoma location, hematoma morphology, hematoma density and other imaging characteristics | Within 1 month of onset | |
Primary | CTA imaging markers | The patient will undergo CTA imaging to evaluate the cerebrovascular features of the patient | Within 1 month of onset | |
Primary | MR imaging markers | Magnetic resonance imaging was performed to evaluate the patient's hematoma morphology, signal, and edema around the hematoma cavity | Within 1 month of onset | |
Secondary | Glasgow Outcome Scale Extended (GOSE) | GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. | 1 year | |
Secondary | modified Rankin scale (mRS) | Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05089331 -
ROSE-Longitudinal Assessment With Neuroimaging
|
||
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Active, not recruiting |
NCT04522102 -
Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase
|
Phase 3 | |
Terminated |
NCT04178746 -
PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
|
||
Not yet recruiting |
NCT03956485 -
Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
|
||
Enrolling by invitation |
NCT02920645 -
Multicenter Validation of the AVICH Score
|
N/A | |
Recruiting |
NCT02625948 -
Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign
|
Phase 2 | |
Completed |
NCT02478177 -
Addressing Real-world Anticoagulant Management Issues in Stroke
|
||
Completed |
NCT01971359 -
Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study
|
N/A | |
Completed |
NCT01261091 -
Early Tracheostomy in Ventilated Stroke Patients
|
N/A | |
Terminated |
NCT00990509 -
Albumin for Intracerebral Hemorrhage Intervention
|
Phase 2 | |
Completed |
NCT00716079 -
The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
|
N/A | |
Recruiting |
NCT00222625 -
rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets
|
Phase 2 | |
Recruiting |
NCT05095857 -
The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
|
Phase 4 | |
Recruiting |
NCT04548596 -
NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
|
||
Not yet recruiting |
NCT06429332 -
International Care Bundle Evaluation in Cerebral Hemorrhage Research
|
Phase 4 | |
Recruiting |
NCT05492474 -
Cranial Ultrasound for Prehospital ICH Diagnosis
|
N/A | |
Not yet recruiting |
NCT05502874 -
Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
|
||
Recruiting |
NCT04604587 -
MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA
|
Phase 3 | |
Recruiting |
NCT05504941 -
Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage
|
N/A |